Midafotel
Midafotel is a drug that was under development for the treatment of stroke and schizophrenia. It acts as an NMDA antagonist, specifically targeting the glutamate site. Midafotel was developed by Pfizer but its development was discontinued in 1998.
History[edit | edit source]
Midafotel was first synthesized by Pfizer in the 1990s as a potential treatment for stroke and schizophrenia. The drug was designed to act as an NMDA antagonist, blocking the action of glutamate at the NMDA receptor. This mechanism of action was thought to be beneficial in the treatment of stroke and schizophrenia, as overactivity of the NMDA receptor has been implicated in both conditions.
However, in 1998, Pfizer discontinued the development of Midafotel. The reasons for this decision are not publicly available, but it is likely that the drug did not meet the necessary safety and efficacy standards in clinical trials.
Mechanism of Action[edit | edit source]
Midafotel acts as an NMDA antagonist, specifically targeting the glutamate site. The NMDA receptor is a type of ionotropic glutamate receptor, and it plays a key role in synaptic plasticity and memory function. Overactivity of the NMDA receptor has been implicated in a number of neurological and psychiatric disorders, including stroke and schizophrenia.
By blocking the action of glutamate at the NMDA receptor, Midafotel was designed to reduce the overactivity of the receptor and thereby alleviate the symptoms of stroke and schizophrenia.
Clinical Trials[edit | edit source]
While the specific details of the clinical trials conducted on Midafotel are not publicly available, it is known that the drug was tested in both stroke and schizophrenia patients. However, the drug did not meet the necessary safety and efficacy standards, leading to the discontinuation of its development.
See Also[edit | edit source]
References[edit | edit source]
| Midafotel Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
